Philips touts data showing iFR beats FFR in 1-year MACE rates for acute coronary disease
Royal Philips (NYSE:PHG) said a meta-analysis of 1-year data from the Define Flair and iFR Swedeheart studies showed that the rate of major cardiac events was higher for patients with acute coronary disease when treatment was deferred using fractional flow reserve than when instant wave-free ratio guidance was used.
The MACE rates were not significantly different for treatments deferred after iFR for acute versus stable coronary disease, according to the meta-analysis, but FFR was associated with higher MACE rates for acute patients than for stable patients
“The pooled data indicate that an iFR-guided strategy is associated with consistent outcomes in [acute coronary disease] and [stable coronary disease] patients who were deferred from treatment in the Define Flair and iFR Swedeheart studies,” the Dutch healthcare giant said.
Philips said it also plans to introduce its iFR Roadmap coronary navigation tech and its SyncVision iFR tech, which is designed to map pressure gradients into angiograms for stenting complex lesions, both part of its Azurion image-guided angiography platform.
“As we celebrate 40 years of innovation in angioplasty, it’s incredible to see how far we’ve come,” image guided therapy systems business leader Ronald Tabaksblat said in prepared remarks. “From guiding the 1st balloon angioplasty catheters to aiding state-of-the-art interventions of today, and tomorrow, with the introduction of Philips Azurion, our next-generation image guided therapy platform. We are dedicated to dramatically transforming our technologies to better address physician and patient needs. At EuroPCR, we’re demonstrating this commitment with our integrated solutions that seamlessly connect people, technologies, and care protocols across the health continuum.”